Cardiff Oncology (CRDF) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Cardiff Oncology is expected to report Q3 2026 results after market close on November 5, with analysts forecasting a loss of $0.138 per share and revenue of $0.08 million.
• The company reported a larger-than-expected Q2 loss of $0.14 per share, while revenue of $0.10 million exceeded estimates; analysts project full-year and next-year losses of $0.60 and $0.56 per share, respectively.
• CRDF shares recently traded at $0.90, near their 12-month low, and analysts collectively maintain a “Hold” rating with a $7.50 average price target despite mixed rating changes.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1380) per share and revenue of $0.08 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.06 million. On average, analysts expect Cardiff Oncology to post ($0.60) EPS for the current fiscal year and ($0.56) EPS for the next fiscal year.

Cardiff Oncology Stock Up 2.6%

CRDF stock opened at $0.90 on Thursday. The business's fifty day simple moving average is $1.08 and its two-hundred day simple moving average is $1.47. Cardiff Oncology has a twelve month low of $0.76 and a twelve month high of $3.31. The firm has a market cap of $69.82 million, a price-to-earnings ratio of -1.50 and a beta of 1.42.

Wall Street Analyst Weigh In

CRDF has been the subject of a number of recent analyst reports. Weiss Ratings lowered shares of Cardiff Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 23rd. HC Wainwright upgraded shares of Cardiff Oncology from a "neutral" rating to a "buy" rating in a report on Tuesday, September 15th. William Blair downgraded shares of Cardiff Oncology from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Cardiff Oncology from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cardiff Oncology has an average rating of "Hold" and an average target price of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company's lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.